Today, doctors are increasingly looking at the genetic makeup of each patient’s tumor to guide treatment decisions.

Braftovi plus Erbitux and FOLFIRI showed significant ORR benefits in BRAF V600E–mutant mCRC compared to the control regimen. The combination therapy achieved a confirmed ORR of 64.4% versus 39.2% with ...

(RTTNews) - Guardant Health, Inc. (GH) said Thursday that the U.S. Food and Drug Administration has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic for patients with BRAF ...

This week in oncology, regulatory updates and practice-changing trial data took center stage. From FDA timeline extensions to ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...

Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without ...

BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in progression-free survival in BRAF V600E-mutant metastatic colorectal cancer Results ...

Circulating tumor DNA profiling and its association with clinical outcomes in metastatic colorectal cancer: Insights from the FRESCO-2 study. This is an ASCO Meeting Abstract from the 2026 ASCO ...